Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vocimagene amiretrorepvec-flucytosine gene therapy - Denovo Biopharma

Next Previous
Search
Drug Profile

Vocimagene amiretrorepvec-flucytosine gene therapy - Denovo Biopharma

Alternative Names: DB-107; DB107-FC; DB107-RRV; Flucytosine prodrug activating therapy - Forte Biosciences; Retroviral replicating viral; RRV; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosine

Latest Information Update: 11 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tocagen
  • Developer Denovo Biopharma; National Cancer Institute (USA); Tocagen
  • Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Immunotherapies; Pyrimidinones; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Gene transference; Prodrug activators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anaplastic astrocytoma; Glioma
  • Discontinued Bladder cancer; Breast cancer; Glioblastoma; Solid tumours

Most Recent Events

  • 08 Jan 2025 Phase-I/II clinical trials in Glioma (First-line therapy, Combination therapy) in USA (IV) (NCT06504381)
  • 08 Jan 2025 Phase-I/II clinical trials in Glioma (First-line therapy, Combination therapy) in USA (PO) (NCT06504381)
  • 16 Jul 2024 University of California plans a phase I/II trial for Glioma (First line therapy, Combination therapy) in USA (Intracerebral, IV, PO)(NCT06504381)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top